Toronto Dominion Bank
VRDN icon

Toronto Dominion Bank’s Viridian Therapeutics VRDN Stock Holding History

Toronto Dominion Bank’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-940
Closed -$18.4K – 2485
2026
Q1 		$18.4K Buy
+940
New +$27.9K ﹤0.01% 1871

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Toronto Dominion Bank's VRDN Position: Q2 2026 in Review

Toronto Dominion Bank sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 940 shares — an estimated $18.4K sold.

Toronto Dominion Bank first reported a position in VRDN in Q1 2026 and held it in 1 quarter. The position peaked at $18.4K in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Toronto Dominion Bank reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Toronto Dominion Bank sold 940 Viridian Therapeutics shares in Q2 2026, an estimated $18.4K.
  • Toronto Dominion Bank first reported a position in Viridian Therapeutics in Q1 2026 and held it in 1 quarter.
  • Toronto Dominion Bank's Viridian Therapeutics position peaked at $18.4K in Q1 2026.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Toronto Dominion Bank's 13F filing for Q2 2026, filed 14 Aug 2026.